SELECT PUBLICATIONS

There is a significant body of literature on both the anti-cancer and anti-viral properties of the Erimos portfolio of proprietary small molecules from which we are developing new therapeutics to treat cancer, viral and autoimmune diseases. The compounds in development constitute a class of drugs that prevent cell replication and enhance the body’s ability to eliminate abnormal cells and viral infection.

Key cancer-related references include:
Mode of Action

Lopez, R.A. (2006). “Terameprocol (EM-1421) inhibits production of Vascular Endothelial Growth Factor (VEGF) in patients with refractory solid tumors.” In: American Association for Cancer Research Annual Meeting: Proceedings; 2007 Apr 14–18; Los Angeles, CA. Philadelphia (PA): AACR; 2007. Abstract 944.

Ambrosini, G., C. Adida, et al. (1998). “Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting.” J Biol Chem 273(18): 11177–82.

Chang, C.C., J.D. Heller, et al. (2004). “Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression.” Proc Natl Acad Sci U S A 101(36): 13239–44.

Heller, J.D., J. Kuo, et al. (2001). “Tetra-O-methyl nordihydroguaiaretic acid induces G2 arrest in mammalian cells and exhibits tumoricidal activity in vivo.” Cancer Res61(14): 5499–504.

 

Terameprocol’s tumoricidal activity when delivered into a variety of animal tumor model systems

Lopez, R.A, Goodman, A.B., et al. (2007). “The anticancer activity of the transcription inhibitor terameprocol (meso-tetra-o-methyl nordihydroguaiaretic acid) formulated for systemic administration.” Anti-Cancer Drugs (In press).

Park, R., C.C. Chang, et al. (2005). “Systemic treatment with tetra-O-methyl nordihydroguaiaretic acid suppresses the growth of human xenograft tumors.” Clin Cancer Res11(12): 4601–9.

Lambert, J.D., R.O. Meyers, et al. (2001). “tetra-O-methylnordihydroguaiaretic acid inhibits melanoma in vivo.” Cancer Lett 171(1): 47–56.

Heller, J.D., J. Kuo, et al. (2001). “Tetra-O-methyl nordihydroguaiaretic acid induces G2 arrest in mammalian cells and exhibits tumoricidal activity in vivo.” Cancer Res61(14): 5499–504.

Key references to NDGA derivatives as viral therapies include:

Park, R., P.E. Giza, et al. (2003). “Inhibition of HSV-1 replication and reactivation by the mutation-insensitive transcription inhibitor tetra-O-glycyl-nordihydroguaiaretic acid.” Antiviral Res 58(1): 35–45.

Gnabre, J.N., J.N. Brady, et al. (1995). “Inhibition of human immunodeficiency virus type 1 transcription and replication by DNA sequence-selective plant lignans.” Proc Natl Acad Sci U S A 92(24): 11239–43.

Key references to Terameprocol (EM-1421) clinical studies include:

Grossman, S.A., Ye, X., et al. (2012). "Phase I study of Terameprocol in patients with recurrent high-grade glioma." Neuro-oncology 14: 511-7.

Tibes, et al. (2015). "Phase 1 Study of Terameprocol (EM-1421) in Patients with Leukemia." Investigational New Drugs 33(2): 389-396.

© 2017 Erimos Pharmaceuticals, LLC